← Oncology Approval Tracker

FDA DECISION ·

Grafapex

treosulfan · medac

FDA approvalNew therapyAllogeneic transplant conditioning for AML or MDS
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With fludarabine as conditioning before allogeneic hematopoietic stem cell transplantation in adults and children age 1 year or older with AML or myelodysplastic syndrome.

LAMPGEN ANALYSIS

Why it matters

The approval establishes a treosulfan-based conditioning option for patients with AML or MDS proceeding to allogeneic transplant.

What research teams should watch

Coordinate dosing and drug supply against the donor graft date and record conditioning deviations in the transplant schedule.

PRIMARY RECORDS

Sources